Format

Send to

Choose Destination
J Biotechnol. 2014 Dec 20;192 Pt A:177-8. doi: 10.1016/j.jbiotec.2014.07.006. Epub 2014 Jul 18.

Complete genome sequence of Salmonella enterica serovar Typhimurium VNP20009, a strain engineered for tumor targeting.

Author information

1
Department of Biological Sciences, Life Sciences I, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA.
2
Department of Biological Sciences, Life Sciences I, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA. Electronic address: bscharf@vt.edu.

Abstract

A mutagenized and genetically modified derivative of Salmonella enterica serovar Typhimurium 14028S, VNP20009 (ATCC 202165), is attenuated in host virulence and accumulates preferentially in tumors. Here, we report the complete genome of this anticancer therapy agent consisting of one chromosome and one virulence plasmid. The major genetic features that distinguish VNP20009 from its parental strain are: an engineered msbB deletion, a 3'-extension in pykA, a Tn10-caused 16.6-kbp inversion leading to the disruption of purM, a 108-kbp Suwwan deletion resulting in the loss of 128 genes, and 50 non-synonymous SNPs.

KEYWORDS:

Anticancer therapy; Attenuated; Auxotrophic; Phase I clinical trial; Tumor colonization

PMID:
25046822
DOI:
10.1016/j.jbiotec.2014.07.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center